The fully human autologous anti-CD19 CAR T-cell therapy, KYV-101, is currently under investigation in several multicenter clinical trials in patients with lupus nephritis, stiff person syndrome, myasthenia gravis, and multiple sclerosis to determine its therapeutic durability and safety profile. This evidence concerns the gene CD19 and myasthenia gravis.